{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:36:47Z","timestamp":1778776607875,"version":"3.51.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dysregulated interleukin (IL)-17\/IL-23 signalling contributes to psoriasis pathogenesis. Cedirogant is an inverse agonist of nuclear receptor ROR-gamma isoform 2 (RORyt), a key transcription factor responsible for IL-17 synthesis and a regulator of the T helper 17 cell lineage programme.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of cedirogant to treat moderate-to-severe psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this phase IIb, multicentre, double-blind, 16-week study (NCT05044234), adults aged 18\u201365 years were randomized 1 : 1 : 1 : 1 to once-daily oral cedirogant 75 mg, 150 mg, 375 mg or placebo. Assessments included: \u2265 50%\/75%\/90%\/100% improvement from baseline in Psoriasis Area and Severity Index (PASI 50\/75\/90\/100), static Physician\u2019s Global Assessment 0\/1, Psoriasis Symptoms Scale 0 and improvements in itch; adverse events (AEs); pharmacokinetics; and IL-17A\/F biomarker levels. Efficacy results based on observed cases were summarized descriptively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 156 enrolled patients, most were male (70.5%); 39 patients were randomized to each treatment. Only 47 patients completed the study; the study was terminated early owing to preclinical findings. At week 16, PASI 75 achievement rates (primary endpoint) were 29%, 8% and 42% in the cedirogant 75-mg, 150-mg and 375-mg groups, respectively, and 0% in the placebo group. AE rates were similar in the cedirogant 75-mg, 150-mg and placebo groups, and higher in the cedirogant 375-mg group; most AEs were mild or moderate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with psoriasis who received cedirogant showed PASI improvement, and cedirogant was generally well tolerated. The results should be interpreted in the context of early study termination. Cedirogant development has been discontinued.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae152","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T09:41:22Z","timestamp":1714729282000},"page":"1347-1355","source":"Crossref","is-referenced-by-count":11,"title":["Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial"],"prefix":"10.1093","volume":"49","author":[{"given":"Stephen","family":"Tyring","sequence":"first","affiliation":[{"name":"Center for Clinical Studies, Department of Dermatology, McGovern School of Medicine, University of Texas Health Science Center , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Moore","sequence":"additional","affiliation":[{"name":"Arlington Research Center , Arlington, TX ,","place":["USA"]},{"name":"Department of Dermatology, Baylor University Medical Center , Dallas, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimchi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H Chih-ho","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science, University of British Columbia , Vancouver, BC ,","place":["Canada"]},{"name":"Probity Medical Research , Surrey, BC ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Ho","family":"Song","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Eccleston","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gweneth","family":"Levy","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed-Eslam F","family":"Mohamed","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8986-2189","authenticated-orcid":false,"given":"Yuli","family":"Qian","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshuang","family":"Wu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anqi","family":"Pan","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinjal","family":"Hew","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Research and Probity Medical Research , Waterloo, ON ,","place":["Canada"]},{"name":"Department of Medicine, University of Toronto , Toronto, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"2024102416193666700_llae152-B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of psoriasis: a comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J Autoimmun"},{"key":"2024102416193666700_llae152-B2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"2024102416193666700_llae152-B3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/ni.1882","article-title":"The dual nature of TH17 cells: shifting the focus to function","volume":"11","author":"O\u2019Connor","year":"2010","journal-title":"Nat Immunol"},{"key":"2024102416193666700_llae152-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","volume":"28","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"2024102416193666700_llae152-B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","volume":"10","author":"Venken","year":"2019","journal-title":"Nat Commun"},{"key":"2024102416193666700_llae152-B6","article-title":"43882 Pharmacokinetics, safety, and efficacy of cedirogant (ABBV-157) in patients with moderate-to-severe plaque psoriasis","volume":"89","author":"D\u2019Cunha","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024102416193666700_llae152-B7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1080\/17460441.2021.1948833","article-title":"Retinoic acid-related orphan receptor gamma t (ROR\u03b3t) inverse agonists\/antagonists for the treatment of inflammatory diseases \u2013 where are we presently?","volume":"16","author":"Gege","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"2024102416193666700_llae152-B8","doi-asserted-by":"crossref","first-page":"e13682","DOI":"10.1111\/cts.13682","article-title":"Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"2024102416193666700_llae152-B9","doi-asserted-by":"crossref","first-page":"AB75","DOI":"10.1016\/j.jaad.2023.07.305","article-title":"43131 Population pharmacokinetic and pharmacodynamic analyses of cedirogant in healthy subjects and subjects with moderate to severe psoriasis","volume":"89","author":"Maier","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024102416193666700_llae152-B10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024102416193666700_llae152-B11","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024102416193666700_llae152-B12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024102416193666700_llae152-B13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program for evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024102416193666700_llae152-B14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"O\u2019Connor","year":"2009","journal-title":"Nat Immunol"},{"key":"2024102416193666700_llae152-B15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae152\/58616130\/llae152.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae152\/60035485\/llae152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae152\/60035485\/llae152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T16:19:52Z","timestamp":1729786792000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/11\/1347\/7663625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,10,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae152","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,5,3]]}}}